These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 25034484)

  • 21. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
    Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
    Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
    Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
    Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
    Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously.
    Cheng HR; Kao JH; Wu HL; Chen TC; Tseng TC; Liu CH; Su TH; Chen PJ; Chen DS; Liu CJ
    Liver Int; 2014 Jul; 34(6):e71-9. PubMed ID: 24119014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD56
    Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
    J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
    Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype F of hepatitis B: response to interferon.
    Venegas M; Poniachik J; Fuster F; Hurtado C; Villanueva RA; Brahm J
    Antivir Ther; 2015; 20(4):453-6. PubMed ID: 25321866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RIG-I enhances interferon-α response by promoting antiviral protein expression in patients with chronic hepatitis B.
    Wu S; Lin J; Fu Y; Ou Q
    Antivir Ther; 2018; 23(7):575-583. PubMed ID: 29790851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.